Harnessing AI to Design Antibodies Against Complex Targets in Autoimmune Diseases and Oncology

Biolojic Design uses proprietary computer-guided techniques to design novel antibodies against complex therapeutic targets.

Historically, the Company operated a service model of drug discovery partnerships and collaborations with Big Pharma but has since evolved to develop its own pipeline of proprietary drugs.

Using 3D computer modeling, the Company is able to characterize binding sites with a very high degree of precision and then make amino acid level changes to known antibodies to dramatically improve their functionality.

Investing partner / fund: